2,089.00
+2.00
(0.10%)
Real-time:
4:17pm BST
LON real-time data - Disclaimer
Currency in GBX unless noted
| Range | 2,059.00 - 2,099.00 |
| 52 week | 1,682.00 - 2,235.00 |
| Open | 2,079.00 |
| Vol / Avg. | 1.30M/1.78M |
| Mkt cap | 11,568.02M* |
| P/E | 32.82 |
| Div/yield | 9.39/0.53* |
| EPS | 0.64* |
| Shares | 553.76M |
| Beta | - |
| Inst. own | - |
| *GBP |
Events
Jul 25, 2013
Q2 2013 Shire Plc Earnings Release
Jun 18, 2013
Shire Plc at Citi European Healthcare Conference
May 30, 2013
Shire Plc at Deutsche Bank dbAccess Health Care Conference
May 2, 2013
Q1 2013 Shire Plc Earnings Conference Call
May 2, 2013
Q1 2013 Shire Plc Earnings Release
Apr 30, 2013
Shire Plc Annual Shareholder Meeting
Apr 23, 2013
Shire Plc at Biotechnology Industry Organization (BIO) International Convention
|
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | 5.54% | 15.90% |
| Operating margin | 11.11% | 20.28% |
| EBITD margin | - | 27.02% |
| Return on average assets | 3.47% | 10.87% |
| Return on average equity | 6.85% | 21.31% |
| Employees | 5,367 | - |
| Carbon Disclosure Rating | - | 77/100 |
Address
Citywest Business Campus 5 Riverwalk, Dublin 24
DUBLIN, ENG
Ireland
+353-1-4297700 (Phone)
DUBLIN, ENG
Ireland
+353-1-4297700 (Phone)
Website links
External links
Analyst Estimates - BusinessWeek
Options - MarketWatch
Research Reports - Reuters
Director Dealings - Yahoo Finance
Discussion Group - Google Finance
Advertisement
Description
Shire plc (Shire) is a specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), gastrointestinal (GI) diseases, human genetic therapies (HGT) and regenerative medicine (RM), as well as opportunities in other therapeutic areas. As of December 31, 2012, the Company�s products included VYVANSE/VENVANSE (lisdexamfetamine dimesylate), ADDERALL XR (mixed salts of a single-entity amphetamine), INTUNIV (extended release guanfacine), EQUASYM (methylphenidate hydrochloride) modified release (XL), LIALDA (mesalamine)/ MEZAVANT(mesalazine), PENTASA (mesalamine), RESOLOR (prucalopride), FOSRENOL (lanthanum carbonate), XAGRID (anagrelide hydrochloride), REPLAGAL (agalsidase alfa), ELAPRASE (idursulfase), VPRIV (velaglucerase alfa), FIRAZYR (icatibant) and DERMAGRAFT(Human Fibroblast-Derived Dermal Substitute). In March 2013, it announced the acquisition Of Premacure AB.
Officers and directors
| Flemming Ornskov M.D. | Chief Executive Officer, Director | |
| Graham Hetherington | Chief Financial Officer, Executive Director | |
| Jeff Jonas M.D. | President - Regenerative Medicine | |
| Tatjana May | General Counsel, Company Secretary | |
| Matthew W. Emmens | Non-Executive Chairman of the Board | |
| David J. Kappler | Senior Independent Non-Executive Deputy Chairman of the Board | |
| William Burns | Non-Executive Independent Director | |
| Steven Gillis Ph.D. | Non-Executive Independent Director | |
| David Ginsburg M.D. | Non-Executive Independent Director |
